CTOs on the Move

Quentis Therapeutics

www.quentistx.com

 
Quentis is at the forefront of the next generation of immuno-oncology companies that are translating novel biology into new therapeutic approaches to help more patients benefit from immunotherapy.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.quentistx.com
  • 430 E 29th St Suite 1005
    New York, NY USA 10016
  • Phone: 646.440.9249

Executives

Name Title Contact Details

Funding

Quentis Therapeutics raised $48M on 02/27/2018

Similar Companies

Flame Biosciences

Flame Biosciences is a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer and other inflammatory conditions.

Adicet Bio

Adicet Bio, Inc. is a publicly held biotechnology company (Nasdaq: ACET) discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

Medarray

Medarray is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alsius Corporation

Alsius Corporation (Alsius) is a commercial-stage medical device company that develops, manufactures and sells products to precisely control patient temperature in hospital critical care settings. The Company operates through its wholly owned subsidiary,

Pyxis Oncology

Founded by Longwood Fund, Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis is employing site-specific conjugation technology to develop highly stable ADCs with enhanced therapeutic indexes. Pyxis is also advancing a diverse portfolio of immunotherapies that target broad immune regulators as well as novel immune checkpoints identified through its immuno-oncology and cold tumor discovery efforts.